Home > Urology > EAU 2021 > Prostate Cancer > 177Lu-PSMA-617: A new class of effective therapy

177Lu-PSMA-617: A new class of effective therapy

Presented By
Prof. Johann de Bono; Prof. Michael Hofman
EAU 2021
Despite recent therapeutic advances, metastatic castration-resistant prostate cancer (mCRPC) remains invariably fatal. The VISION study showed for men with advanced-stage prostate-specific membrane antigen (PSMA)-positive mCRPC after androgen receptor pathway inhibition and chemotherapy, adding 177Lu-PSMA-617 to standard-of-care treatment extended both overall survival (OS) and radiographic progression-free survival (rPFS). In addition, 177Lu-PSMA-617 was well tolerated. PSMA is highly expressed in many but not all prostate cancer cells. 177Lu-PSMA-617 is a targeted radioligand therapy that delivers β-particle radiation, which induces DNA damage and double-strand breaks, to PSMA-expressing cells and surrounding microenvironment, destroying cancer cells. VISION In the phase 3 VISION trial (NCT03511664), 831 patients were randomised ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on